当前位置: 首页 >> 检索结果
1021. Clinical and ultrasound features of a cohort of psoriasis patients without musculoskeletal symptoms: a prospective and multicentre study.
作者: Ana Belén Azuaga.;Andrea Cuervo.;Delia Reina.;Paula Estrada-Alarcón.;Lourdes Mateo.;María Aparicio.;Mireia Moreno.;Marta Arévalo.;Ana Láiz.;Patricia Moya.;Lucía Alascio.;Josep Riera.;José U Scher.;Juan D Cañete.;Julio Ramírez.
来源: Rheumatology (Oxford). 2025年64卷10期5396-5403页
To evaluate clinical and ultrasound (US) features related to psoriatic arthritis (PsA) development in psoriasis (PsO), patients without musculoskeletal (MSK) symptoms and no systemic treatment.
1022. Frequency-specific microcurrent improves hand function and Raynaud's symptoms in scleroderma: results of two pilot studies.
作者: Walter M Gregory.;Katherine Bagley.;Sookhoe Eng.;Carolyn McMakin.;Francesco Del Galdo.
来源: Rheumatology (Oxford). 2025年64卷10期5504-5508页
To evaluate the efficacy of frequency-specific microcurrent as a treatment designed to improve hand function and alleviate Raynaud's symptoms in patients with systemic sclerosis.
1023. Single-centre comparison of non-familial, familial and monogenic lupus.
作者: Jalila Alshekaili.;Batool S H Al Lawati.;Zahran Althuhli.;Warda Al-Azri.;Almundher Al-Maawali.;Samiya Al-Rashdi.;Farida Al-Mamari.;Mahmood Al-Kindi.;Hamad Al Balushi.;Mohammed Al-Rawahi.;Murtadha Al-Khabori.;Matthew C Cook.
来源: Rheumatology (Oxford). 2025年64卷10期5388-5395页
There is a significant genetic contribution to systemic lupus erythematosus (SLE). Monogenic SLE is a distinct form of SLE. We investigated whether familial or known monogenic lupus cases are distinguishable from non-familial lupus by clinical or laboratory phenotype in a population with high rates of consanguinity.
1024. Impact of immune checkpoint TIGIT on the activation and function of natural killer cells in rheumatoid arthritis patients.
作者: Ming Zhao.;Rui Ma.;Changsheng Xia.;Jinghong Feng.;Wenyi Li.;Yan Long.
来源: Rheumatology (Oxford). 2025年64卷9期5151-5161页
This study aims to investigate the changes of circulating natural killer (NK) cells and their TIGIT expression diversities, and further explore the impact of TIGIT expression on the activity and function of NK cells in rheumatoid arthritis (RA) patients.
1025. JAK inhibitors alleviate metabolic dysregulation, inflammation and fibrosis in osteoarthritis: insights from human joint cells and synovium.
作者: Geneviève Paulissen.;Olivier Malaise.;Céline Deroyer.;Edith Charlier.;Sophie Neuville.;Zelda Plener.;Thierry Thirion.;Christophe Daniel.;Clio Ribbens.;Dominique de Seny.
来源: Rheumatology (Oxford). 2025年64卷10期5539-5550页
Osteoarthritis (OA) presents a significant clinical challenge due to its heterogeneous nature, characterized by cartilage degradation, inflammation and fibrosis. Current treatments offer limited efficacy, highlighting the need for novel therapeutic approaches. Our study aimed to investigate the effects of two Janus kinase (JAK) inhibitors, tofacitinib and baricitinib, on various hallmarks of OA in human joint cells and synovium.
1026. Safety of biologic therapy in kidney and liver transplant recipients with systemic inflammatory diseases: a real-world study from Israel.
作者: Victoria Furer.;Omer Kersh.;Mark Berman.;Ayelet Grupper.;Liane Rabinowich.;Hagit Peleg.;Elisheva Pokroy-Shapira.;Ori Elkayam.
来源: Rheumatology (Oxford). 2025年64卷10期5372-5378页
Safety is a concern for solid-organ transplant (SOT) recipients with systemic inflammatory diseases (SIDs) treated with biologic therapy. This study evaluated the safety of biologic therapy in SOT recipients with SIDs.
1028. Long-term effects of selexipag in SSc-associated digital ulcers: a case-control multicentre observational study.
作者: Claudia Iannone.;Marco Di Battista.;Maria Rosa Pellico.;Ilaria Magi.;Antonina Minniti.;Giuseppe Armentaro.;Silvia Cavalli.;Manuel Sette.;Laura Giudice.;Cristina Bochicchio.;Alessandra Della Rossa.;Antonio G Tavoni.;Fabio Cacciapaglia.;Stefano Stano.;Martina Orlandi.;Dilia Giuggioli.;Marta Mosca.;Roberto Caporali.;Nicoletta Del Papa.
来源: Rheumatology (Oxford). 2025年64卷10期5364-5371页
Digital ulcers (DUs) affect ∼50% of SSc patients, causing significant pain and functional impairment. Current management involves both systemic and local therapies. However, the burden in terms of pain and quality of life due to refractory DUs still remains heavy. While selexipag is approved for SSc-associated pulmonary arterial hypertension, its potential in treating DUs is unexplored. We aimed to evaluate the long-term efficacy of selexipag compared with iloprost in treating DUs.
1029. Predictive factors and clinical outcomes of progressive pulmonary fibrosis in anti-threonyl (PL7) positive anti-synthetase syndrome.
作者: Xueyan Shan.;Zhenguo Huang.;Guochun Wang.;Yongpeng Ge.
来源: Rheumatology (Oxford). 2025年64卷10期5379-5387页
Patients with anti-threonyl (PL7) positive anti-synthetase syndrome (ASS) exhibit a high prevalence of interstitial lung disease (ILD), which can progress to progressive pulmonary fibrosis (PPF) and increased mortality. This study aims to explore the clinical characteristics, imaging features and predictive factors for PPF.
1030. High levels of EPSTI1 enhance IFN-β-mediated HLA-A expression and chemokine secretion in myoblasts in dermatomyositis.
作者: Xiaojing Li.;Ting Ding.;Yizhi Xiao.;Junyu Zhou.;Ting Huang.;Shasha Xie.;Qiming Meng.;Weijia He.;Hongling Zhu.;Hui Luo.
来源: Rheumatology (Oxford). 2025年64卷10期5529-5538页
Epithelial-Stromal Interaction 1 (EPSTI1), an IFN-related gene that has emerged as a gene of notable interest, plays a multifaceted role in cellular function and disease processes. However, the precise role of EPSTI1 in the context of DM remains elusive and requires further exploration.
1031. Predicting trajectories of lung function decline in systemic sclerosis-related interstitial lung disease.
作者: Boyang Zheng.;Mandana Nikpour.;Wendy Stevens.;Susanna Proudman.;Kathleen Morrisroe.;Mianbo Wang.;Ada Man.;Murray Baron.; .
来源: Rheumatology (Oxford). 2025年64卷11期5892-5898页
SSc-related interstitial lung disease (SSc-ILD) is a major cause of morbidity. We aimed to identify patients following similar trajectories of forced vital capacity (FVC) decline, and examine their association with mortality and risk factors for FVC decline.
1032. Lung function and skin fibrosis changes as predictors of survival in SSc-associated interstitial lung disease: a EUSTAR study.
作者: Vincent Sobanski.;Jeska de Vries-Bouwstra.;Anna-Maria Hoffmann-Vold.;Dörte Huscher.;Margarida Alves.;Marco Matucci-Cerinic.;Gabriela Riemekasten.;Mengtao Li.;László Czirják.;Otylia Kowal-Bielecka.;Yannick Allanore.;Nils Schoof.;Oliver Distler.; .
来源: Rheumatology (Oxford). 2025年64卷10期5344-5353页
This study assessed how changes in lung function, skin fibrosis and digital ulceration (DU) burden predict mortality in patients with SSc-associated interstitial lung disease (SSc-ILD), the leading cause of death in SSc.
1033. Temporal trends in vascular medication use in 8079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort.
作者: Stefano Di Donato.;John D Pauling.;Sheila Ramjug.;Yannick Allanore.;Edward B Jude.;Marie-Elise Truchetet.;Paolo Airò.;Lidia P Ananyeva.;Andra Balanescu.;Gonçalo Boleto.;Francesco Paolo Cantatore.;Patricia E Carreira.;Carolina de Souza Müller.;Masataka Kuwana.;Gianluca Moroncini.;Marco Di Battista.;Luc Mouthon.;Madelon C Vonk.;Elisabetta Zanatta.;Marco Matucci-Cerinic.;Francesco Del Galdo.;Michael Hughes.; .
来源: Rheumatology (Oxford). 2025年64卷10期5354-5363页
Systemic sclerosis (SSc) is characterized by widespread vascular damage resulting in digital and systemic vasculopathic sequelae. Although there are effective treatments available, vascular disease remains a significant cause of morbidity and mortality in SSc. Our aim was to describe patterns of vascular medication use in SSc, including examination for potential changes over time.
1034. Lung transplantation outcomes of patients with interstitial pneumonia with autoimmune features: a single-centre retrospective cohort study.
作者: Alec Chu Ming Yu.;Hyein Kim.;Robert D Levy.;Jennifer M Wilson.;Darya S Jalaledin.;James Choi.;John Yee.;Charles D Poirier.;Sabrina Anh-Tu Hoa.;Océane Landon-Cardinal.;Kun Huang.
来源: Rheumatology (Oxford). 2025年64卷10期5338-5343页
Interstitial pneumonia with autoimmune features (IPAF) describes patients with interstitial lung disease (ILD) and autoimmune features without meeting criteria for a specific rheumatic disease. No longitudinal data exist on post-transplant outcomes in IPAF patients. We compared baseline demographics, pre-transplant characteristics and post-transplant outcomes between IPAF and idiopathic pulmonary fibrosis (IPF) patients undergoing double lung transplantation.
1035. Switching to IL-6 inhibitors or abatacept in elderly patients with rheumatoid arthritis achieving low disease activity with JAK inhibitors: a pilot study.
作者: Shunichi Fujita.;Yoshitaka Morita.;Kazuhisa Nakano.
来源: Rheumatology (Oxford). 2025年64卷9期5182-5183页 1037. Long-term effectiveness of non-surgical interventions for chronic low back pain: a systematic review and meta-analysis.
作者: Hazel J Jenkins.;Leticia Corrêa.;Benjamin T Brown.;Giovanni E Ferreira.;Casper Nim.;Sasha L Aspinall.;Deborah Wareham.;Junghyun Choi.;Christopher G Maher.;Mark J Hancock.
来源: Lancet Rheumatol. 2025年7卷9期e607-e617页
Chronic low back pain is a long-term recurrent condition. Interventions with sustained benefits are needed to reduce the associated personal and societal burden. We aimed to assess the long-term effectiveness of non-surgical interventions for reducing pain intensity and disability in adults with chronic low back pain.
1038. Cardiovascular and venous thromboembolic events in systemic sclerosis: epidemiological analysis of the Clinical Practice Research Datalink.
作者: John D Pauling.;Rachel Charlton.;Laura Ross.;Neil J McHugh.;Anita McGrogan.
来源: Rheumatology (Oxford). 2025年64卷10期5330-5337页
Cardiovascular disease is a leading cause of mortality in systemic sclerosis (SSc). We investigated the association between SSc and the occurrence of both cardiovascular and thromboembolic events using the Clinical Practice Research Datalink (CPRD).
1039. Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study.
作者: Michel Moutschen.;Cécile Boulanger.;Joke Dehoorne.;Rik Joos.;Florence Roufosse.;Vito Sabato.;Jeroen van der Hilst.;Eleonore Maury.;Hilde Rabijns.;Marijn Witterzeel.;Carine Wouters.
来源: BMC Rheumatol. 2025年9卷1期64页
Canakinumab, an IL-1β inhibitor, has demonstrated long-term efficacy and safety in patients with sJIA, FMF, TRAPS, and MKD/HIDS who experience inadequate disease control with conventional treatments. This non-interventional study aimed to gain insights into canakinumab use and treatment patterns for these diseases in Belgium.
1040. Interferon-γ release assay as an emergent powerful biomarker in systemic lupus erythematosus.
作者: Yves Renaudineau.;Emmanuel Treiner.;Fabrice Herin.;Stanislas Faguer.;Gregory Pugnet.;Laurent Sailler.
来源: Rheumatology (Oxford). 2025年64卷10期5313-5321页
To investigate the ex vivo IFN-γ release assay (IGRA) as a biomarker of systemic lupus erythematosus (SLE) activity and disease outcome.
|